Display options
Cite
Vernole P, Concato C, Pianca C, et al. Association of cytogenetic abnormalities in a neuroblastoma and fragile sites expression. Br J Cancer. 1988;58(3):287-91doi: 10.1038/bjc.1988.205.
Vernole, P., Concato, C., Pianca, C., Nicoletti, B., & Melino, G. (1988). Association of cytogenetic abnormalities in a neuroblastoma and fragile sites expression. British journal of cancer, 58(3), 287-91. https://doi.org/10.1038/bjc.1988.205
Vernole, P, et al. "Association of cytogenetic abnormalities in a neuroblastoma and fragile sites expression." British journal of cancer vol. 58,3 (1988): 287-91. doi: https://doi.org/10.1038/bjc.1988.205
Vernole P, Concato C, Pianca C, Nicoletti B, Melino G. Association of cytogenetic abnormalities in a neuroblastoma and fragile sites expression. Br J Cancer. 1988 Sep;58(3):287-91. doi: 10.1038/bjc.1988.205. PMID: 3179179; PMCID: PMC2246604.
Copy Download .nbib Format: NLM
Share it on
Full text links
Nature Publishing Group Free PMC Article

Br J Cancer. 1988 Sep;58(3):287-91. doi: 10.1038/bjc.1988.205.

Association of cytogenetic abnormalities in a neuroblastoma and fragile sites expression.

British journal of cancer

P Vernole, C Concato, C Pianca, B Nicoletti, G Melino

Affiliations

  1. Dip. Sanità Pubblica e Biologia Cellulare, Il Università Tor Vergata, Roma, Italy.

PMID: 3179179 PMCID: PMC2246604 DOI: 10.1038/bjc.1988.205
Free PMC Article

Abstract

A 15 month old boy with a stage IV right suprarenal gland neuroblastoma showed a number of raised biochemical parameters, whilst catecholamines and skeletal survey were normal. Treatment with peptichemio failed to give a clinical response. Histological evidence of neuroblastoma infiltration in the bone marrow aspirate was absent. Immunofluorescence on sedimented cells was negative using antibody UJ223.8, PI153/3 and H11; only UJ308 and to a lesser extent UJ13A gave positive results. After 21 days, however, the same cells in culture showed highly differentiated dendritic processes. Thirty-seven percent metaphases from bone marrow aspirate showed the following karyotype 45XY, del (1) (p32), and two markers. Mar1 = der (2) t (2; 2) (2qter----2q14::2p24----2qter). Mar2 = der (15) t (15; 2) (15qter----15p11::2p11----2pter). Treatment with methotrexate reduced the aberrant mitoses rate to 2%. N-myc in situ hybridisation showed significant signal on both markers confirming the cytogenetic interpretation. Peripheral blood lymphocytes at 72 h showed a higher level of breaks per cell than control. After treatment with aphidicolin (APC) or methotrexate (MTX) for the last 24 h, to induce fragile sites, the incidence of breaks per cells was increased. Moreover 11.4% of APC-induced breaks were in 1p31-32 (mean of normal controls = 2.3%). The mother presented an increased sensitivity to the inducibility of fragile sites, while the father's lymphocytes showed values within the control range. The genetic changes produced by the abnormalities on chromosomes 1 and 2 might be related to tumour progression. Furthermore this is the first description of correlation between a high frequency of fragile site 1p31-32 induced by APC in the patient's lymphocytes and deletion of 1p32 in tumour cells. The interpretation of these findings and of other similar correlations needs further study.

References

  1. Cancer Genet Cytogenet. 1984 Oct;13(2):185-8 - PubMed
  2. J Natl Cancer Inst. 1984 Aug;73(2):405-16 - PubMed
  3. Science. 1984 Dec 7;226(4679):1199-204 - PubMed
  4. Mol Cell Biol. 1984 Nov;4(11):2370-80 - PubMed
  5. Cancer Genet Cytogenet. 1986 Jan 1;19(1-2):101-11 - PubMed
  6. Cytogenet Cell Genet. 1985;40(1-4):490-535 - PubMed
  7. Cancer. 1986 May 1;57(9):1887-93 - PubMed
  8. J Cancer Res Clin Oncol. 1986;111(3):266-72 - PubMed
  9. Cancer. 1986 Dec 1;58(11):2453-8 - PubMed
  10. Cancer Res. 1987 Jan 1;47(1):311-8 - PubMed
  11. Cancer Genet Cytogenet. 1987 Jun;26(2):235-44 - PubMed
  12. Am J Med Genet. 1987 Jun;27(2):471-82 - PubMed
  13. Cancer Res. 1987 Aug 1;47(15):4146-9 - PubMed
  14. Nature. 1987 Aug 6-12;328(6130):524-6 - PubMed
  15. Lancet. 1971 Oct 30;2(7731):971-2 - PubMed
  16. Cancer Res. 1978 Nov;38(11 Pt 1):3751-7 - PubMed
  17. Cytogenet Cell Genet. 1979;23(3):208-12 - PubMed
  18. Cytogenet Cell Genet. 1978;22(1-6):352-6 - PubMed
  19. N Engl J Med. 1980 May 29;302(22):1254-6 - PubMed
  20. Chromosoma. 1981;83(3):431-9 - PubMed
  21. Cancer Res. 1981 Nov;41(11 Pt 1):4678-86 - PubMed
  22. Lancet. 1983 Jan 1;1(8314-5):12-5 - PubMed
  23. Cell. 1983 Feb;32(2):311-5 - PubMed
  24. Nature. 1983 Sep 15-21;305(5931):245-8 - PubMed
  25. Nature. 1983 Nov 17-23;306(5940):277-80 - PubMed
  26. Lancet. 1984 Mar 17;1(8377):593-5 - PubMed
  27. N Engl J Med. 1984 Jul 26;311(4):231-5 - PubMed
  28. Cancer Res. 1984 Nov;44(11):5444-9 - PubMed

MeSH terms

Publication Types

LinkOut - more resources